Stock Price Quote

SOLARA ACTIVE PHARMA SCIENCES LTD.

NSE : SOLARABSE : 541540ISIN CODE : INE624Z01016Industry : Pharmaceuticals & DrugsHouse : Private
BSE490.25-11.8 (-2.35 %)
PREV CLOSE ( ) 502.05
OPEN PRICE ( ) 512.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 14997
TODAY'S LOW / HIGH ( )476.95 512.00
52 WK LOW / HIGH ( )321.93 885.95
NSE490.50-9.45 (-1.89 %)
PREV CLOSE( ) 499.95
OPEN PRICE ( ) 508.80
BID PRICE (QTY) 490.50 (1)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 85339
TODAY'S LOW / HIGH( ) 474.95 524.90
52 WK LOW / HIGH ( )322.52 882.8
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 23-02 2017
Management Info
R Ramakrishnan - Chairman Poorvank Purohit - Managing Director
Registered Office

Address 201, Devavrata,Sector 17,Vashi,
Navi Mumbai,
Maharashtra-400703

Phone 022 2789 2924 / 2789 3199

Email investors@solara.co.in

Website www.solara.co.in

Registrars Details
Cameo Corporate Services Ltd
Subramanian Buildings No 1 ,Club House Road,,Chennai
Listing : BSE, NSE

NEWS

07Feb Solara Active Pharma Sciences informs
With reference to earlier letter dated January 24, 2025 whereby the Comp..
31Jan Solara Active Pharma Sciences informs
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..
29Jan Solara Active Pharma Sciences informs
Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated..
16Jan Solara Active Pharma Sciences informs
Solara Active Pharma Sciences has informed that Company, as part of inve..
16Jan Solara Active Pharma Sciences informs
Solara Active Pharma Sciences has informed that a meeting of Board of Di..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit81.0000000000002-5668.7
Gross Profit 81.0000000000002 -4883.3
Operating Profit 591.8-896.9
Net Sales 3003.112889.2

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Ajanta Pharma (BSE)
peergroup  2558.40 (2.61%)
M.Cap ( in Cr)31957.51
Coral Laboratories (BSE)
peergroup  807.60 (8.54%)
M.Cap ( in Cr)288.52
Vimta Labs (BSE)
peergroup  1119.70 (3.91%)
M.Cap ( in Cr)2488.29
Mercury Laboratories (BSE)
peergroup  849.00 (3.78%)
M.Cap ( in Cr)101.88
Aarti Drugs (BSE)
peergroup  410.85 (7.20%)
M.Cap ( in Cr)3749.83

Shareholding Pattern

NON-INSTITUTION 44.91%
PROMOTERS 37.23%
MUTUAL FUNDS/UTI 1.28%
FI/BANKS/INSURANCE 0.03%
GOVERNMENT 0%
FII 0%

About Solara Active Pharma Sciences Ltd.

Solara Active Pharma Sciences Ltd. was incorporated in the year 2017. Its today's share price is 490.25. Its current market capitalisation stands at Rs 2355.8 Cr. In the latest quarter, company has reported Gross Sales of Rs. 12889.2 Cr and Total Income of Rs.12942.9 Cr. The company's management includes S Murali Krishna, Mohan Muthunarayanan, Poorvank Purohit, Manish Gupta, Kartheek Chintalapati Raju, Arun Kumar, Rajiv Vijay Nabar, Rajendra Kumar Srivastava, Kausalya Santhanam, R Ramakrishnan.

It is listed on the BSE with a BSE Code of 541540 , NSE with an NSE Symbol of SOLARA and ISIN of INE624Z01016. It's Registered office is at 201, Devavrata,Sector 17,VashiNavi Mumbai-400703, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.